title: A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation.
abstract: We present the establishment of a natural killer (NK) leukemia cell line, designated KHYG-1, from the blood of a patient with aggressive NK leukemia, which both possessed the same p53 point mutation. The immunophenotype of the primary leukemia cells was CD2+, surface CD3-, cytoplasmic CD3epsilon+, CD7+, CD8alphaalpha+, CD16+, CD56+, CD57+ and HLA-DR+. A new cell line (KHYG-1) was established by culturing peripheral leukemia cells with 100 units of recombinant interleukin (IL)-2. The KHYG-1 cells showed LGL morphology with a large nucleus, coarse chromatin, conspicuous nucleoli, and abundant basophilic cytoplasm with many azurophilic granules. The immunophenotype of KHYG-1 cells was CD1-, CD2+, surface CD3-, cytoplasmic CD3epsilon+, CD7+, CD8alphaalpha+, CD16-, CD25-, CD33+, CD34-, CD56+, CD57-, CD122+, CD132+, and TdT-. Southern blot analysis of these cells revealed a normal germline configuration for the beta, delta, and gamma chains of the T cell receptor and the immunoglobulin heavy-chain genes. Moreover, the KHYG-1 cells displayed NK cell activity and IL-2-dependent proliferation in vitro, suggesting that they are of NK cell origin. Epstein-Barr virus (EBV) DNA was not detected in KHYG-1 cells by Southern blot analysis with a terminal repeat probe from an EBV genome. A point mutation in exon 7 of the p53 gene was detected in the KHYG-1 cells by PCR/SSCP analysis, and direct sequencing revealed the conversion of C to T at nucleotide 877 in codon 248. The primary leukemia cells also carried the same point mutation. Although the precise role of the p53 point mutation in leukemogenesis remains to be clarified, the establishment of an NK leukemia cell line with a p53 point mutation could be valuable in the study of leukemogenesis.
authors.affiliation: Department of Clinical Immunology and Hematology, Tazuke-Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Yagita
authors.forename: C L
authors.initials: CL
authors.lastname: Huang
authors.forename: H
authors.initials: H
authors.lastname: Umehara
authors.forename: Y
authors.initials: Y
authors.lastname: Matsuo
authors.forename: R
authors.initials: R
authors.lastname: Tabata
authors.forename: M
authors.initials: M
authors.lastname: Miyake
authors.forename: Y
authors.initials: Y
authors.lastname: Konaka
authors.forename: K
authors.initials: K
authors.lastname: Takatsuki
mesh_terms: D015703:Antigens, CD / Q000032:analysis; D018929:Cell Culture Techniques / Q000379:methods; D002460:Cell Line; D016207:Cytokines / Q000032:analysis; D003602:Cytotoxicity, Immunologic; D005260:Female; D016158:Genes, p53; D006801:Humans; D016130:Immunophenotyping; D007376:Interleukin-2 / Q000494:pharmacology; D007621:Karyotyping; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology* / Q000473:pathology*; D015458:Leukemia, T-Cell / Q000235:genetics / Q000276:immunology* / Q000473:pathology*; D008875:Middle Aged; D017354:Point Mutation; D011994:Recombinant Proteins / Q000494:pharmacology
chemical_list: D015703:Antigens, CD; D016207:Cytokines; D007376:Interleukin-2; D011994:Recombinant Proteins